×

Herborium's CEO Will Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on January 17th, 2015

Fort Lee, New Jersey, USA, Jan. 16, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc.(OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company providing unique, all botanical medicines (Botanical Therapeutics®), announced today that the Company's CEO, Dr. Agnes P. Olszewski will be interviewed live by Michael Yorba, the host, on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show on January 17th, 2015.

Dr. Olszewski will speak about Herborium's recent growth, its opportunities and how the Company's innovative business model capitalizes on the changing landscape of healthcare and wellness sectors to ensure a continuous success of Botanical Therapeutics® .

Date: January 17, 2015

Start Time: 1:00pm ET |10:00am PT | 12:00pm CT (U.S.)

Network: Clear Channel - iHeart

Station: DFW 1190AM

KFXR Show: The Trader's Network 


Host: Michael Yorba 


Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Clear Channel

Clear Channel's Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About The Traders Network Show

For the past six years "The Traders Network Show" has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am - 7:30am and 2pm - 3pm CT, Monday-Friday. Host, Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. With focus on "tomorrow's ideas today".

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, and www.acnease.com.

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.

CONTACT: Herborium Group, Inc. Email: InvestorsRelations@Herborium.com or Customerservice@herborium.com Tel. 1.201.849.4431

Source:Herborium Group, Inc.